Table 1.
Cohort characteristics
| Median age at death (IQR) | n female (%) | RIN FCX (IQR) | n total | |
|---|---|---|---|---|
| Controls | 86.5 (79.3–89.8) | 16 (66.7) | 9.1 (8.7–9.8) | 24 |
| FTLD-TDP-A | 83 (79–86.8) | 12 (50.0) | 9.5 (9.0–9.7) | 25 |
| FTLD-TDP-B | 66.5 (58.5–72) | 10 (50.0) | 9.8 (9.0–9.9) | 20 |
| FTLD-TDP-C | 74.5 (67.8–78) | 8 (36.4) | 9.3 (8.7–9.7) | 22 |
| GRN mutation carriers | 66.5 (64–75.8) | 14 (56.0) | 8.9 (8.2–9.5) | 24 |
Information is shown for FTLD-TDP patients without mutation in the known genes, control participants without neurological diseases (Controls) and patients carrying a pathogenic mutation in the GRN gene (GRN mutation carriers). Age at death, RNA integrity number (RIN), number (n) of female participants and pathological diagnosis (FTLD-TDP-A, FTLD-TDP-B, FTLD-TDP-C) are specified. Data presented are median age at death [interquartile range (IQR)] or n and percentages (%).